Graybug Vision, Inc. (GRAY)
Stock Price:
$15.89 USD
-0.42 (-2.58%)
Updated Oct 21, 2020 2:39 PM EDT - Market open
Key Info
| Market Cap |
319.28M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-34.14M |
| Shares Out |
19.16M |
| EPS (ttm) |
-1.78 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 21, 2020 |
| Last Price |
$15.89 |
| Previous Close |
$16.31 |
| Change ($) |
-0.42 |
| Change (%) |
-2.58% |
| Day's Open |
16.67 |
| Day's Range |
15.25 - 16.67 |
| Day's Volume |
57,010 |
| 52-Week Range |
12.50 - 20.74 |
More Stats
| Market Cap |
319.28M |
| Enterprise Value |
301.74M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
19.16M |
| Float |
12.62M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-1.78 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
174,598 |
| Short Ratio |
0.27 |
| Short % of Float |
1.38% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
20.32 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
-34.14M |
| Free Cash Flow |
n/a |
| Net Cash |
17.54M |
| Net Cash / Share |
0.87 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -37.50 | -28.57 |
| Net Income | -37.04 | -28.38 |
| Shares Outstanding | 11.89 | 11.43 |
| Earnings Per Share | -3.71 | -2.86 |
| Operating Cash Flow | -31.22 | -28.22 |
| Capital Expenditures | -0.61 | -1.46 |
| Free Cash Flow | -31.82 | -29.68 |
| Cash & Equivalents | 35.96 | 12.83 |
| Net Cash / Debt | 35.96 | 12.83 |
| Assets | 40.66 | 17.81 |
| Liabilities | 144 | 84.61 |
| Book Value | -103 | -66.79 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Graybug Vision, Inc. |
| Country |
United States |
| Employees |
24 |
| CEO |
Frédéric Guerard |
Stock Information
| Ticker Symbol |
GRAY |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: GRAY |
| IPO Date |
September 25, 2020 |
Description
Graybug Vision, a clinical stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. Its lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. The company is also developing GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was founded in 2011 and is based in Redwood City, California.